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Background: The environmental pollutant 2,3,7,8-tetrachloro
dibenzo-p-dioxin (TCDD) is the most toxic among the dioxin
xenobiotics and induces a broad spectrum of biological
responses, including immunotoxicity and cancer [1]. Macro-
phages are very plastic cells and can acquire various function-
ally distinct phenotypes depending on the physiological
context. They are key regulators of the innate immune response
and determine the developmental thrust of the adaptive
immune response. The action of TCDD on macrophages is
unique in that carried out through a variety of pathways, induc-
ing activation of a number of cytokines [2]. Our previous analysis
showed that the list of such cytokines was not complete [3].
IL-12 family of cytokines is the key players in the regulation of
T cell responses. Little is known of the effects that TCDD has
on the expression of IL-12 family member’s genes, such as
IL12A, IL12B, IL27 and EBI3, which forms a critically important
cytokines IL-12 and IL-27, secreted by human macrophages. In
the present work, the effects of TCDD on expression of IL-12
family member’s genes in human macrophages have been
investigated.
Results: To examine the effects of TCDD on the functional
characteristics of macrophages, experiments have been con-
ducted on the monocyte-like cell line U937 and primary human
macrophages. Obtained data demonstrate functional activity of
DREs in IL12A, IL12B and IL4 gene promoters via AhR signal
pathway. The mRNA expression dynamics of IL12A, IL12B, IL4,
IL27 and EBI3 cytokines genes also evidence the indirect
TCDD–mediated modulation of these genes via intrinsic TFs,
one of which is ATF3.
Conclusion: Exposure to TCDD induces a mechanism of two-
stage regulation of the expression of some IL-12 family subunits
through primary activation of the aryl hydrocarbon receptor by
the TCDD-containing complex followed by ATF3-dependent sup-
pression of their expression. This may result in an abrupt reduc-
tion of the anti-tumor response mediated by O and NK cells. The
observed increase in ATF3 and decrease in IL-12 following expo-
sure to TCDD are consistent with data on the expression of these
genes in tumor-associated macrophages (TAMs). Reliance upon
available data that demonstrate a decrease in IL-12 alongside an
increase in the expression of other cytokines typical of TAMs con-
firms the hypothesis that TCDD can shift the phenotype of a
macrophage towards a tumor-associated direction. This mecha-
nism may be one of the others underlying TCDD-driven tumor
promotion.
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Existing methods for the preoperative detection of metastases
in thyroid cancer have low efficiency and highly invasive.
Therefore, the searches for laboratory markers that will indicate
the presence of metastases including hidden with high reliability
in cancer of the thyroid gland are relevant.
Immune system is one of the key mechanisms for regulation
of tissue proliferation. Autoreactive lymphocytes restrict the
growth and proliferation of tissues. In turn autoreactive lympho-
cytes are controlled by idiotypic lymphocytes. Abnormalities in
the regulation system can be the cause of tumor growth, such
as excess activity of anti-idiotypic lymphocytes. Previously we
conducted a comparative analysis of the level of autoantibodies
to various antigens (thyroglobulin, thyroid stimulating hormone
receptor, native DNA, anionic proteins vascular endothelium),
as well as anti-idiotypic antibodies to thyroglobulin in thyroid
cancer patients with metastases and without metastases. Signif-
icant differences between investigated groups were found in the
level of anti-idiotypic antibodies against antibodies to thyroglob-
ulin. Therefore, the aim of this study was to analyze the feasibil-
ity of using anti-idiotypic antibodies against antibodies to
thyroglobulin as a marker of metastatic thyroid cancer.
All studied patients with thyroid cancer were hospitalized at
Primushko Regional Clinical Oncology Center of the Ministry of
Health of the Udmurt Republic, Izhevsk. Blood was taken from
patients before surgery. The level of anti-idiotype antibodies
(AIAT) against autoantibodies to thyroglobulin (Tg) and the level
of autoantibodies (AUAT) to thyroglobulin were determined in
the blood plasma using the test system manufacturing MRC
”Immunkulus”. To determine the AIAT against AUAT to Tg, we
used the principle of competitive inhibition of the binding reac-
tion with antibodies to thyroglobulin in the presence of analyzed
serum. As a source of antibodies to thyroglobulin, we used serum
from patients with autoimmune thyroiditis in effective dilutions
for competition. Analyzed samples were previously depleted by
antibodies to thyroglobulin. The level of the test antibodies was
expressed in conventional unit (CU) - optical density of the reac-
tion of antibody binding to the antigen.
We found that AIAT against AUAT to Tg were not defined in
43% of thyroid cancer patients with metastases (group I), 57%
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